Pivotal bioVenture Partners Investment Advisor’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,494,851
| Closed | -$18M | – | 11 |
|
|
2025
Q2 | $18M | Hold |
4,494,851
| – | – | 11.14% | 4 |
|
|
2025
Q1 | $4.09M | Hold |
4,494,851
| – | – | 3.31% | 5 |
|
|
2024
Q4 | $12.5M | Hold |
4,494,851
| – | – | 8.41% | 4 |
|
|
2024
Q3 | $23.5M | Hold |
4,494,851
| – | – | 13.95% | 2 |
|
|
2024
Q2 | $20M | Hold |
4,494,851
| – | – | 15.41% | 2 |
|
|
2024
Q1 | $34.4M | Hold |
4,494,851
| – | – | 22.13% | 2 |
|
|
2023
Q4 | $19.1M | Hold |
4,494,851
| – | – | 4.86% | 4 |
|
|
2023
Q3 | $18.9M | Buy |
4,494,851
+833,333
| +23% | +$4.24M | 7.53% | 4 |
|
|
2023
Q2 | $20.4M | Buy |
3,661,518
+447,932
| +14% | +$2.65M | 6.72% | 4 |
|
|
2023
Q1 | $18.4M | Buy |
3,213,586
+552,432
| +21% | +$1.46M | 7.58% | 3 |
|
|
2022
Q4 | $2.79M | Hold |
2,661,154
| – | – | 1.22% | 8 |
|
|
2022
Q3 | $7.13M | Hold |
2,661,154
| – | – | 2.61% | 6 |
|
|
2022
Q2 | $12.7M | Buy |
2,661,154
+1,070,000
| +67% | +$4.65M | 6.39% | 4 |
|
|
2022
Q1 | $6.51M | Hold |
1,591,154
| – | – | 3.08% | 8 |
|
|
2021
Q4 | $10.9M | Hold |
1,591,154
| – | – | 4.54% | 7 |
|
|
2021
Q3 | $18.4M | Hold |
1,591,154
| – | – | 6.52% | 6 |
|
|
2021
Q2 | $27.1M | Hold |
1,591,154
| – | – | 10.69% | 4 |
|
|
2021
Q1 | $31.5M | Hold |
1,591,154
| – | – | 10.11% | 3 |
|
|
2020
Q4 | $32.8M | Buy |
+1,591,154
| New | +$37.9M | 10.83% | 4 |
|
Pivotal bioVenture Partners Investment Advisor's INZY Position: Q3 2025 in Review
Pivotal bioVenture Partners Investment Advisor sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 4,494,851 shares — an estimated $18M sold.
Pivotal bioVenture Partners Investment Advisor first reported a position in INZY in Q4 2020 and held it in 19 quarters. The position peaked at $34.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Pivotal bioVenture Partners Investment Advisor reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Pivotal bioVenture Partners Investment Advisor sold 4,494,851 Inozyme Pharma shares in Q3 2025, an estimated $18M.
- Pivotal bioVenture Partners Investment Advisor first reported a position in Inozyme Pharma in Q4 2020 and held it in 19 quarters.
- Pivotal bioVenture Partners Investment Advisor's Inozyme Pharma position peaked at $34.4M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2025, filed 13 Nov 2025.